Pharmacological or siRNA-mediated inhibition of AR was demonstrated to inhibit the proliferation of colon cancer cells associated with downregulation of hypoxia-inducible factor-1α (HIF-1α) and its downstream target, vascular endothelial growth factor (VEGF), a potent proangiogenic protein. Here, AR is linked to malignant colon neoplasm.